回复 @雪崩:跌到8_老虎社区_美港股上老虎 - 老虎社区

回复 @雪崩:跌到80后就能逐步建仓，买正股加卖call增加收益。如果财报后能降期权iv，可能是期权进场的良机//@雪崩:看来100只是起点，机构反着看。缺口补完，财报下跌后，差不多可以再进了。

@孟浩：BMO下调吉利德评级，吉利德下跌3.36%

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":922603836,"tweetId":"922603836","gmtCreate":1587524972225,"gmtModify":1704364579673,"author":{"id":338241771329220,"idStr":"338241771329220","authorId":338241771329220,"authorIdStr":"338241771329220","name":"骑马看戏","avatar":"https://static.tigerbbs.com/88e9ccceb7ce2a97bbad215077ce2c8a","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":10,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>\n 回复 @雪崩:跌到80后就能逐步建仓，买正股加卖call增加收益。如果财报后能降期权iv，可能是期权进场的良机//@雪崩:看来100只是起点，机构反着看。缺口补完，财报下跌后，差不多可以再进了。</body></html>","htmlText":"<html><head></head><body>\n 回复 @雪崩:跌到80后就能逐步建仓，买正股加卖call增加收益。如果财报后能降期权iv，可能是期权进场的良机//@雪崩:看来100只是起点，机构反着看。缺口补完，财报下跌后，差不多可以再进了。</body></html>","text":"回复 @雪崩:跌到80后就能逐步建仓，买正股加卖call增加收益。如果财报后能降期权iv，可能是期权进场的良机//@雪崩:看来100只是起点，机构反着看。缺口补完，财报下跌后，差不多可以再进了。","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/922603836","repostId":922840329,"repostType":1,"repost":{"magic":2,"id":922840329,"tweetId":"922840329","gmtCreate":1587517561455,"gmtModify":1704364547508,"author":{"id":58341441844653,"idStr":"58341441844653","authorId":58341441844653,"authorIdStr":"58341441844653","name":"孟浩","avatar":"https://static.tigerbbs.com/d3af5b59c3e4676ee72cb6e0fea0279b","vip":2,"userType":2,"introduction":"互联网从业，专注美港股投资","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.18","individualDisplayEnabled":0},"individualDisplayBadges":[{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","templateUuid":"3f8f4b8c193b4343a88817ce07587dbd","name":"星级创作者","description":"社区优质创作者：发表过3篇及以上精华帖，且30天内发表过至少一篇精华帖并参与过评论","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":0,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.12.24","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"}}],"fanSize":37923,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"BMO下调吉利德评级，吉利德下跌3.36%","extraTitle":"","html":"<html><head></head><body><p>BMO Capital Markets将该股评级从强于大盘下调至大盘</p> <p> <span>BMO Capital Markets</span>分析师认为，尽管投资者对瑞德西韦感到兴奋，因为<span>瑞德西韦</span>是一种用于治疗**患者试验性药物，但由于<span>瑞德西韦</span>的商业机会持续存在不确定性，他们“不再认为股票有有利的风险/回报。” 他们写道，研发中的预防病毒感染的疫苗的进展，引发了对感染后治疗的持久性的质疑。</p> <p>他们指出，罗氏公司的达菲流感治疗在2009年H1N1流感大流行期间创造了超过30亿美元的收入，但在那之后，该药物的年销售额平均为6.7亿美元。 今年迄今，吉利德的股价上涨了29.6%，而标准普尔500指数则下跌了11.0%。<a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a><a href=\"https://laohu8.com/S/RHHBY\">$罗氏控股(RHHBY)$</a> </p></body></html>","htmlText":"<html><head></head><body><p>BMO Capital Markets将该股评级从强于大盘下调至大盘</p> <p> <span>BMO Capital Markets</span>分析师认为，尽管投资者对瑞德西韦感到兴奋，因为<span>瑞德西韦</span>是一种用于治疗**患者试验性药物，但由于<span>瑞德西韦</span>的商业机会持续存在不确定性，他们“不再认为股票有有利的风险/回报。” 他们写道，研发中的预防病毒感染的疫苗的进展，引发了对感染后治疗的持久性的质疑。</p> <p>他们指出，罗氏公司的达菲流感治疗在2009年H1N1流感大流行期间创造了超过30亿美元的收入，但在那之后，该药物的年销售额平均为6.7亿美元。 今年迄今，吉利德的股价上涨了29.6%，而标准普尔500指数则下跌了11.0%。<a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a><a href=\"https://laohu8.com/S/RHHBY\">$罗氏控股(RHHBY)$</a> </p></body></html>","text":"BMO Capital Markets将该股评级从强于大盘下调至大盘 BMO Capital Markets分析师认为，尽管投资者对瑞德西韦感到兴奋，因为瑞德西韦是一种用于治疗**患者试验性药物，但由于瑞德西韦的商业机会持续存在不确定性，他们“不再认为股票有有利的风险/回报。” 他们写道，研发中的预防病毒感染的疫苗的进展，引发了对感染后治疗的持久性的质疑。 他们指出，罗氏公司的达菲流感治疗在2009年H1N1流感大流行期间创造了超过30亿美元的收入，但在那之后，该药物的年销售额平均为6.7亿美元。 今年迄今，吉利德的股价上涨了29.6%，而标准普尔500指数则下跌了11.0%。$吉利德科学(GILD)$$罗氏控股(RHHBY)$","highlighted":1,"essential":1,"paper":2,"link":"https://laohu8.com/post/922840329","repostId":0,"isVote":1,"tweetType":1,"commentLimit":10,"symbols":["GILD","RHHBY"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":523,"xxTargetLangEnum":"ZH_CN"},"isVote":1,"tweetType":1,"viewCount":735,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":167,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/922603836"}